Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...

The results showed that people who took sotagliflozin had a 23% lower risk of heart attacks, strokes, and death from ...

A recent study has found that a class of diabetes drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors may increase ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Mesoblast's high-risk programs drive inflated valuation. Find out why MESO stock remains a "sell" as execution risks outweigh ...

A team of researchers, led by one of Indian origin, has found that a drug recently approved by the US Food and Drug Administ ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...